Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer.

ABSTRACT: Iron accumulation in tumors contributes to disease progression and chemoresistance. Although targeting this process can influence various hallmarks of cancer, the immunomodulatory effects of iron chelation in the tumor microenvironment are unknown. Here, we report that treatment with deferiprone, an FDA-approved iron chelator, unleashes innate immune responses that restrain ovarian cancer. Deferiprone reprogrammed ovarian cancer cells toward an immunostimulatory state characterized by the production of type-I IFN and overexpression of molecules that activate NK cells. Mechanistically, these effects were driven by innate sensing of mitochondrial DNA in the cytosol and concomitant activation of nuclear DNA damage responses triggered upon iron chelation. Deferiprone synergized with chemothera

SUBMITTER: Sandoval TA 

PROVIDER: S-EPMC11452292 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature